Last reviewed · How we verify
NCT06091410
Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines
Phase 4 trial testing Omicron-containing COVID-19 vaccine in COVID-19 in 62 participants. Status unknown.
25 February 2025
Quick facts
| Lead sponsor | Catholic Kwandong University |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | basic science |
| Enrollment | 62 |
| Start date | 25 September 2023 |
| Primary completion | 25 February 2025 |
| Estimated completion | 25 June 2025 |
| Sites | 2 locations across South Korea |
Drugs / interventions tested
- Omicron-containing COVID-19 vaccine — full drug profile →
- influenza vaccine — full drug profile →
Conditions studied
- COVID-19 — all drugs for COVID-19 →
- Influenza — all drugs for Influenza →
- Vaccine Reaction — all drugs for Vaccine Reaction →
- Contaminant Injected — all drugs for Contaminant Injected →
Sponsor
Catholic Kwandong University
Who can join
Adults 18 to 65, any sex, with COVID-19 or Influenza. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal is to evaluate the in-depth immunogenicity analysis (including B-cell and T-cell response) of coadministration of a omicron-containing COVID-19 vaccine and influenza vaccine among healthy adults during 2023-24 season.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06091410
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for COVID-19
Currently open trials in the same condition.
- NCT07183709 — Safety and Immunogenicity Trial of PepGNP-COVID19 Vaccine in Adults · Phase 1 · active not recruiting
- NCT07300839 — A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age · Phase 3 · active not recruiting
- NCT07221162 — A Safety and Immunogenicity Trial of Boost-2867 Vaccine, Via Intranasal and Intramuscular Routes · Phase 1 · recruiting
- NCT07215520 — Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults · Phase 2 · recruiting
- NCT07222384 — A Study to Learn About BNT162b2 (LP.8.1)-Adapted Vaccine Against SARS-CoV-2 in Children 5 Through 11 Years of Age That A · Phase 3 · active not recruiting
Other Catholic Kwandong University trials
Trials by the same sponsor.
- NCT06432894 — Performance Evaluation of ANI in Patients Under General Anesthesia With Remimazolam · recruiting
- NCT05970887 — Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines · Phase 4 · completed
- NCT04056585 — Intermittent Compression Maneuver of Upper Arm to Reduce Axillary Brachial Plexus Block Onset Time · NA · unknown
- NCT03109951 — Abnormal Blood Sugar Tests in Diabetic Patients During Colonoscopy Preparation · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06091410 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Catholic Kwandong University
- Last refreshed: 26 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06091410.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing